The Uromigos

Health EN ↓ 478 episodes

Broadcasting the latest developments in GU cancerHosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer CenterTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Author

The Uromigos

Episodes

Episode 282: Holiday Special: Bladder Cancer in 2023 13.12.2023 38:12

Kala Sridhar discusses all the key trials in 2023. She also reveals her favourite Xmas song.

Episode 281: The Uromigos Paper of the Month - Lu-177 with Pembrolizumab in Prostate Cancer 08.12.2023 25:23

Rahul Aggarwal describes his phase 1/2 study with only 1 cycle of Lu-177 in CRPC.

Episode 280: IKCS 2023 Overview 16.11.2023 35:24

Tian Zhang discusses this fabulous renal cancer meeting. Belzutifan is covered too.

An apology 13.11.2023 1:47

Tom and Brian apologise for the unacceptable words and images which were broadcast by hackers during the Uromigos livestream last week. We’re really sorry and will do everything we can to make sure it never happens again.

Episode 279: Management of IO-resistant RCC at #UromigosLive 2023 06.11.2023 1:00:37

Monty Pal, Toni Chouieri, and Tian Zhang join Tom and Brian to discuss CONTACT-03, TiNivo-2, IO-based therapy, and more. Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.

Episode 278: Current and Future Status of Radioligand Therapy at #UromigosLive 2023 04.11.2023 39:31

Brian is joined by Neeraj Agarwal, Tanya Dorff, Rana McKay, and Michael Morris to review the state of radioligand therapy. The panel examines primary and secondary end points of VISION, current practice patterns, the right way to dose 177Lu-PSMA, PSMAfore, and more. Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.

Episode 277: NMIBC Discussion at #UromigosLive 2023 04.11.2023 44:04

Tom is joined by Sam Chang, Sia Daneshmand, and Petros Grivas to discuss new therapies in non-muscle invasive bladder cancer, including those for BCG-refractory NMIBC and the cretostimogene + pembrolizumab combo for BCG-unresponsive NMIBC. Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.

Episode 276: ESMO 2023 Highlights 28.10.2023 49:08

Silke Gillessen joins Tom and Brian to give a summary of the meeting,

Episode 275: Live meeting preview for #UromigosLive 2023 in Nashville 27.10.2023 13:30

Brian and Tom discuss the benefits and risks of participating in the upcoming meeting . Uncertainty around it’s success are highlighted . Methods of attending remain opaque.

Episode 274: ESMO 2023 STEAP1/BiTE in CRPC shows promise 27.10.2023 19:46

Kevin Kelly described a Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) bispecific T cell engager showing activity in a phase 1 trial in prostate cancer.

Episode 273: ESMO 2023 - Toripalimab and axitinib in clear cell RCC 26.10.2023 13:47

Toripalimab plus axitinib as first-line treatment option for advanced RCC by Xinan Sheng

Episode 272: ESMO 2023 - EV302 and CM901 in 1st line bladder cancer 22.10.2023 31:32

Michiel van der Heijden and Tom discuss EV302 (EVP) and CM901 (chemo/nivo)

Episode 271: ESMO 2023 - THOR: Erdafitinib in bladder cancer 22.10.2023 23:30

Yohann Loriot described the 2 Thor randomised phase 3 studies

Episode 270: ESMO 2023 - Belzutifan in renal cancer 21.10.2023 28:26

Lisa Pickering discusses the 2 randomised trial and the 1st line combination study in renal cancer

Episode 269: ESMO 2023 - antibody drug conjugate doublets in UC 21.10.2023 24:52

Brad McGregor discuses the DAD trial exploring this combo for the 1st time

Episode 268: ESMO 2023 - Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett 20.10.2023 27:06

Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)

Episode 267: ESMO preview - things to look out for at the meeting 11.10.2023 27:05

Silke Gillessen, Brian and Tom look at ESMO 2023 GU track and beyond

Episode 266: Radiotherapy for prostate cancer 10.10.2023 28:45

Nick James discusses the optimal patients for radiotherapy and his approach to perioperative hormone therapy

Episode 265: Brachytherapy with Jeff Michalski 03.10.2023 40:02

Paper of the month: a randomised trial of brachytherapy vs external beam.

Episode 264: Prostatectomy vs RT vs surveillance- the PROTECT trial 27.09.2023 29:51

Jim Catto describes the 17 yr follow up data from this large prostate cancer study.

Episode 263: Toni Choueiri and papillary renal cancer 20.09.2023 36:20

We describes progress in system therapy for advanced papillary RCC. Opportunities and challenges around personalised therapy are discussed

Episode 262: Paper of the month abiraterone +/- cabazitaxel in CRPC. 12.09.2023 30:35

Susan Slovin describes her JCO investigator initiated R2 study which show the addition of cabazitaxel to abiraterone may be of benefit in CRPC

Episode 261: part 2 ctDNA in bladder cancer 04.09.2023 40:29

Matt Galsky completes the discussion on the rapidly moving topic.

Episode 260: Celeste Simon: how to make a career in translation science work. 30.08.2023 26:24

Celeste shares her thoughts on her career in the lab, collaboration and working with clinicians. She also talks about things that went well and things that went less wells

Episode 259: Cystectomy for bladder cancer 24.08.2023 25:29

Jim Catto defends the virtues of cystectomy after last weeks radiotherapy for MIBC podcast with Ananya